Anavex Life Sciences Q3 EPS $(0.14) Misses $(0.13) Estimate

Anavex Life Sciences (NASDAQ:AVXL) reported quarterly losses of $(0.14) per share which missed the analyst consensus estimate of $(0.13) by 7.69 percent. This is a 27.27 percent decrease over losses of $(0.11) per share

byBill Haddad

August 12, 2021

1 minute read

‘China video gaming crackdown: no new titles approved in May, signalling continued Beijing hostility’ -South China Morning Post

By Benzinga Newsdesk

Today, 5:20 AM

https://www.scmp.com/tech/big-tech/article/3179894/china-video-gaming-crackdown-no-new-titles-approved-may-signalling?module=live&pgtype=homepage

FXI

Mesoblast’s Lead Drug Candidate Goes Under FDA Priority Review For Bone Marrow Transplant Complications In Kids

By Vandana Singh

Today, 5:20 AM

Mesoblast Ltd (NASDAQ:MESO) rallied after the FDA agreed to review the company’s lead drug candidate, remestemcel-L, on a priority basis, more…

MESO

U.S. Govt Calls For Additional Doses Of Regeneron’s COVID-19 Antibody Therapy

By Vandana Singh

Today, 5:20 AM

The U.S. government will buy 1.4 million additional doses of Regeneron Pharmaceuticals Inc’s (NASDAQ:REGN) COVID-19 antibody cocktail. Read Next: FDA Expands EUA for…

LLY

Morgan Stanley Maintains Equal-Weight on Air Products & Chemicals, Lowers Price Target to $315

By Benzinga Newsdesk

Today, 5:20 AM

Morgan Stanley analyst Vincent Andrews maintains Air Products & Chemicals (NYSE:APD) with a Equal-Weight and lowers the price target from $335 to $315.

APD

Anavex Life Sciences Q3 EPS $(0.14) Misses $(0.13) Estimate

Related Posts

‘China video gaming crackdown: no new titles approved in May, signalling continued Beijing hostility’ -South China Morning Post

Mesoblast’s Lead Drug Candidate Goes Under FDA Priority Review For Bone Marrow Transplant Complications In Kids

U.S. Govt Calls For Additional Doses Of Regeneron’s COVID-19 Antibody Therapy

Morgan Stanley Maintains Equal-Weight on Air Products & Chemicals, Lowers Price Target to $315